Author:
Zhang Juan,Liu Ying,Lv Jun,Cao Ya,Li Genxi
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Juillerat-Jeanneret L (2014) Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else? J Med Chem 57(6):2197–2212. doi: 10.1021/jm400658e
2. Shimodaira M, Muroya Y, Kumagai N, Tsuzawa K, Honda K (2013) Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with Type 2 diabetes. J Endocrinol Investig 36(9):734–738. doi: 10.3275/8934
3. Holz G (2004) New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells. Horm Metab Res 36(11–12):787–794. doi: 10.1055/s-2004-826165
4. Durinx C, Lambeir AM, Bosmans E, Falmagne JB, Berghmans R, Haemers A, Scharpe S, De Meester I (2000) Molecular characterization of dipeptidyl peptidase activity in serum–soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 267(17):5608–5613. doi: 10.1046/j.1432-1327.2000.01634.x
5. Shane R, Wilk S, Bodnar RJ (1999) Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 815(2):278–286. doi: 10.1016/s0006-8993(98)01121-4
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献